The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.